Drawing for MEDIGENE IMMUNOTHERAPIES

USPTO serial 86605899

MEDIGENE IMMUNOTHERAPIES

Reviewed by CopyMark Law Group

Reg. 5038910Status 710
Filing date
Status date
Registration date
Sep 13, 2016
Examiner
LEASER, ANDREW C
Law office
PUBLICATION AND ISSUE SECTION

What this means

Status 710 means the registration was cancelled because a required Section 8 declaration of continued use was not filed within the deadline (including any grace period). The federal registration is no longer active. Evaluate filing a new application if you still use the mark, or petition if cancellation was erroneous. Consult counsel on remaining common-law rights.

Status 710: Status 710 means the registration was cancelled because a required Section 8 declaration of continued use was not filed within the deadline (including any grace period). The federal registration is no longer active.

Need help with MEDIGENE IMMUNOTHERAPIES?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Leonard P. Linardakis

Leonard P. Linardakis Moser Taboada1030 Broad Street - Suite 203Shrewsbury, NJ 07702UNITED STATES

Goods and services

ClassDescriptionStatusFirst use
005Medicines for humans and animals for the treatment of tumor precursors, benign and malignant tumor diseases, particularly hematological tumor diseases, inflammatory diseases, neurodegenerative diseases, and autoimmune diseases, vaccines, medicated serums for treatment of tumor precursors, benign and malignant tumor diseases, particularly hematological tumor diseases, inflammatory diseases, neurodegenerative diseases, and autoimmune diseases, diagnostic and drug testing kits comprised of medical reagents and assays for testing of bodily fluids for use in disease detection, namely, tumor precursors, benign and malignant tumor diseases, particularly hematological tumor diseases, inflammatory diseases, neurodegenerative diseases, and autoimmune diseases, all prepared by means of molecular biology, genetic engineering or biotechnological methods; substances for medical diagnosis purposes, namely, proteins, nucleic acids, cell products, protein conjugates, peptides, enzymes and enzyme preparations, particularly antibodies and T cell proteins; T cells, dendritic cells, and other cells of the immune system, viruses, and virus-like particles, all for medical purposes; liposomes for medical purposes; plant extracts for medical purposes; low molecular active ingredients, namely, medicines for the treatment of tumor precursors, benign and malignant tumor diseases, particularly hematological tumor diseases, inflammatory diseases, neurodegenerative diseases, and autoimmune diseases, vaccines, adjuvants, serums for treatment of tumor precursors, benign and malignant tumor diseases, particularly hematological tumor diseases, inflammatory diseases, neurodegenerative diseases, and autoimmune diseases, diagnostic and drug testing kits comprised of medical reagents and assays that test for the presence of tumor precursors, benign and malignant tumor diseases, particularly hematological tumor diseases, inflammatory diseases, neurodegenerative diseases, autoimmune diseases and immune therapySECTION 8 - CANCELLED—
042Services of a molecular biology or biotechnology laboratory, particularly research and development work in the field of human medical and veterinary medical diagnosis and therapy by means of molecular biology, genetic engineering or biotechnological methods as well as in the field of screening for pharmaceutically active compounds; design and development of test methods and test kits in the field of biotechnology and medicineSECTION 8 - CANCELLED—
044Medical analyses and medical consultancy in the context of the treatment of single persons, particularly in the field of tumor precursors, benign and malignant tumor diseases, autoimmune diseases and immunotherapySECTION 8 - CANCELLED—
045Licensing of intellectual property, including trademarks and patents in the field of biotechnology, pharmacy, and medicineSECTION 8 - CANCELLED—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Mar 24, 2023C8..CANCELLED SEC. 8 (6-YR)—
Sep 13, 2021REM1COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED—
Sep 13, 2016R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Jun 28, 2016NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Jun 28, 2016PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Jun 8, 2016NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
May 23, 2016PREVLAW OFFICE PUBLICATION REVIEW COMPLETED—
May 13, 2016CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
May 12, 2016TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
May 12, 2016CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
May 6, 2016ARAAATTORNEY/DOM.REP.REVOKED AND/OR APPOINTEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
May 6, 2016REAPTEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED—
May 6, 2016TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Dec 17, 2015DOCKASSIGNED TO EXAMINER—
Nov 9, 2015GNRNNOTIFICATION OF NON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Nov 9, 2015GNRTNON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Nov 9, 2015CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Oct 21, 2015TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Oct 21, 2015CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Oct 14, 2015ALIEASSIGNED TO LIE—
Sep 23, 2015ERSITEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED—
Aug 7, 2015GNS3NOTIFICATION OF LETTER OF SUSPENSION E-MAILED—
Aug 7, 2015GNSLLETTER OF SUSPENSION E-MAILED—
Aug 7, 2015CNSLSUSPENSION LETTER WRITTEN—
Aug 7, 2015XAECEXAMINER'S AMENDMENT ENTERED—
Aug 7, 2015GNENNOTIFICATION OF EXAMINERS AMENDMENT E-MAILED—
Aug 7, 2015GNEAEXAMINERS AMENDMENT E-MAILED—
Aug 7, 2015CNEAEXAMINERS AMENDMENT -WRITTEN—
Jul 31, 2015DOCKASSIGNED TO EXAMINER—
May 2, 2015MPMKNOTICE OF PSEUDO MARK E-MAILED—
May 1, 2015NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Apr 25, 2015NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance